Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination. In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
NANP-specific IgG
Timeframe: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
anti- full lengths CSP IgG
Timeframe: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
anti- C-terminal CSP IgG
Timeframe: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
anti-measles IgG
Timeframe: At 10 months of age (1 month after the first MR dose)